Comprehensive Nursing Assignment: Anemia

Comprehensive Nursing Assignment: Anemia

☝Above Image Generated by AI

1. Introduction

Definition of the Disease

Anemia is a hematological disorder characterized by a reduction in the total number of circulating erythrocytes (red blood cells - RBCs) or a decrease in the quality or quantity of hemoglobin (Hb). According to the World Health Organization (WHO), anemia is defined as a hemoglobin level of less than 13.0 g/dL in men and less than 12.0 g/dL in non-pregnant women.

Brief Overview

Anemia is not a specific disease but rather a clinical sign of an underlying pathology. Because hemoglobin is responsible for transporting oxygen to the body's tissues, a deficit leads to cellular hypoxia. This condition is a global public health concern, disproportionately affecting young children, menstruating individuals, and pregnant women.

2. ANATOMY AND PHYSIOLOGY

Relevant Anatomy Involved

Hematopoietic System:

Bone Marrow

Red bone marrow: Primary site of hematopoiesis in adults
Located in flat bones (sternum, ribs, vertebrae, pelvis, skull) and proximal ends of long bones
Contains hematopoietic stem cells that differentiate into all blood cell lineages

Blood Components

Red blood cells (erythrocytes): 4.5-5.5 million/μL in males; 4.0-5.0 million/μL in females
Hemoglobin: Oxygen-carrying protein within RBCs
Plasma: Liquid component containing nutrients, hormones, and proteins

Organs Involved in RBC Metabolism

Liver: Produces clotting factors, stores vitamin B12 and folate, metabolizes bilirubin
Spleen: Filters old and damaged RBCs, stores iron
Kidneys: Produce erythropoietin (EPO), a hormone stimulating RBC production

Gastrointestinal Tract

Stomach: Produces intrinsic factor for vitamin B12 absorption
Duodenum and upper jejunum: Primary sites of iron absorption
Ileum: Vitamin B12 absorption site

Normal Physiology

Erythropoiesis (RBC Production):

Process Duration: Approximately 7 days from stem cell to mature RBC
Stages of Development:

Pluripotent stem cell → Myeloid stem cell → Proerythroblast → Basophilic erythroblast → Polychromatophilic erythroblast → Orthochromatic erythroblast → Reticulocyte → Mature erythrocyte

Regulatory Mechanisms:

Erythropoietin (EPO): Produced by kidneys in response to hypoxia; stimulates bone marrow to increase RBC production
Oxygen sensing: Hypoxia-inducible factors (HIFs) detect decreased oxygen and trigger EPO production
Negative feedback: Adequate oxygen delivery suppresses EPO production

Essential Requirements for Erythropoiesis:

Iron: Component of heme in hemoglobin (approximately 20-25 mg daily requirement)
Vitamin B12 (cobalamin): DNA synthesis (2.4 μg daily requirement)
Folate (folic acid): DNA synthesis (400 μg daily requirement)
Protein: Globin chain synthesis
Copper, vitamin B6, vitamin C: Cofactors in hemoglobin synthesis
Erythropoietin: Growth factor stimulation

Hemoglobin Structure and Function:

Structure:

Composed of four globin chains (2 alpha, 2 beta in adult hemoglobin A)
Each chain contains a heme group with iron at its center
Each hemoglobin molecule can carry four oxygen molecules

Function:

Oxygen transport from lungs to tissues
Carbon dioxide transport from tissues to lungs
pH buffering in blood

RBC Lifespan and Destruction:

Normal Lifespan: Approximately 120 days
Destruction Process:

Aged RBCs become less flexible and are trapped in splenic sinusoids
Macrophages phagocytize damaged RBCs (extravascular hemolysis)
Hemoglobin is broken down into:

Iron: Recycled for new RBC production or stored as ferritin
Globin: Broken down into amino acids and reused
Heme: Converted to biliverdin, then bilirubin (excreted via bile)

Iron Metabolism:

Absorption: 1-2 mg daily absorbed in duodenum and proximal jejunum
Transport: Bound to transferrin in plasma
Storage: As ferritin and hemosiderin in liver, spleen, and bone marrow
Total Body Iron: Approximately 3-4 grams in adults

65% in hemoglobin
30% in storage (ferritin/hemosiderin)
5% in myoglobin and enzymes

Homeostasis:

Balance between RBC production and destruction maintains normal hemoglobin levels
Daily production equals daily destruction (approximately 1% of RBCs daily)
Regulatory mechanisms adjust production to meet physiological demands

3. ETIOLOGY (CAUSES)

Predisposing Factors

A. Nutritional Deficiencies

Iron Deficiency

Inadequate dietary intake of iron-rich foods
Poor bioavailability of dietary iron (non-heme iron from plant sources)
Increased iron requirements during growth spurts, pregnancy, lactation

Vitamin B12 Deficiency

Strict vegetarian/vegan diet (B12 found primarily in animal products)
Pernicious anemia (autoimmune destruction of gastric parietal cells)
Lack of intrinsic factor production
Gastrectomy or gastric bypass surgery

Folate Deficiency

Poor dietary intake of green leafy vegetables, fruits, and fortified grains
Overcooking of foods (destroys folate)
Increased requirements during pregnancy and lactation

B. Chronic Blood Loss

Gastrointestinal Sources

Peptic ulcer disease
Gastritis (especially NSAID-induced)
Esophageal varices
Hemorrhoids
Colorectal cancer
Inflammatory bowel disease (Crohn's disease, ulcerative colitis)
Parasitic infections (hookworm)

Genitourinary Sources

Menorrhagia (heavy menstrual bleeding)
Uterine fibroids
Hematuria (kidney stones, bladder cancer)

Other Sources

Frequent blood donation
Chronic nosebleeds

C. Impaired RBC Production

Bone Marrow Disorders

Aplastic anemia (bone marrow failure)
Myelodysplastic syndromes
Leukemia
Multiple myeloma
Bone marrow infiltration (metastatic cancer)

Chronic Diseases

Chronic kidney disease (decreased EPO production)
Chronic liver disease
Hypothyroidism
Inflammatory conditions (rheumatoid arthritis, lupus)
Chronic infections (HIV, tuberculosis)
Malignancy

D. Increased RBC Destruction (Hemolytic Anemias)

Inherited Hemolytic Anemias

Sickle cell disease
Thalassemia
Hereditary spherocytosis
G6PD deficiency

Acquired Hemolytic Anemias

Autoimmune hemolytic anemia
Drug-induced hemolysis
Mechanical hemolysis (prosthetic heart valves)
Hemolytic transfusion reactions
Infections (malaria, sepsis)

E. Genetic and Hereditary Factors

Family history of inherited anemias
Genetic mutations affecting hemoglobin synthesis
Ethnic predisposition (thalassemia in Mediterranean, Asian populations; sickle cell in African descent)

Risk Factors

A. Demographic Factors

Age

Infants and young children (rapid growth, dietary inadequacy)
Adolescents (growth spurts, menstruation onset)
Elderly (chronic diseases, poor nutrition, polypharmacy)

Gender

Women of reproductive age (menstrual blood loss)
Pregnancy and lactation (increased iron requirements)

Ethnicity

African descent: Sickle cell disease
Mediterranean, Asian, Middle Eastern: Thalassemia
Northern European: Pernicious anemia

B. Socioeconomic Factors

Poverty and food insecurity
Limited access to healthcare
Poor sanitation (parasitic infections)
Lack of nutrition education

C. Lifestyle Factors

Dietary Habits

Vegetarian/vegan diets without proper supplementation
Excessive tea/coffee consumption (inhibits iron absorption)
Alcohol abuse (folate deficiency, GI bleeding)
Eating disorders (inadequate nutrient intake)

Medications

Chronic NSAID use (GI bleeding)
Anticonvulsants (folate deficiency)
Proton pump inhibitors (decreased B12 and iron absorption)
Metformin (decreased B12 absorption)
Chemotherapy agents (bone marrow suppression)

D. Physiological States

Pregnancy

Increased blood volume (dilutional anemia)
Increased iron requirements for fetal development
Multiple pregnancies with short intervals

Menstruation

Menorrhagia (>80 mL blood loss per cycle)
Frequent menstrual cycles

E. Medical Conditions

Malabsorption syndromes (celiac disease, Crohn's disease)
Chronic kidney disease (stages 3-5)
Cancer (bleeding, bone marrow infiltration, chemotherapy)
Autoimmune disorders
Chronic infections
Endocrine disorders (hypothyroidism)

F. Surgical History

Gastrectomy (decreased intrinsic factor, iron absorption)
Bariatric surgery (malabsorption)
Bowel resection (decreased absorption surface)

G. Environmental Factors

Lead exposure (inhibits heme synthesis)
Living at high altitudes (initially compensatory, then depletion of iron stores)
Parasitic infections in endemic areas

4. PATHOPHYSIOLOGY

Step-by-Step Disease Process

The pathophysiological mechanisms of anemia can be categorized into three primary processes:

A. Decreased RBC Production

1. Iron Deficiency Anemia

Stage 1: Iron Depletion

Dietary intake insufficient to meet body requirements
Iron stores (ferritin) in bone marrow, liver, and spleen become depleted
Serum ferritin levels decrease (<30 ng/mL)
No clinical manifestations at this stage
RBC production remains normal

Stage 2: Iron-Deficient Erythropoiesis

Storage iron completely exhausted
Serum iron decreases, total iron-binding capacity (TIBC) increases
Transferrin saturation falls below 15%
Inadequate iron delivery to developing RBCs
Early biochemical changes appear
Still no anemia present

Stage 3: Iron Deficiency Anemia

Insufficient iron for hemoglobin synthesis
Production of microcytic (small), hypochromic (pale) RBCs
Hemoglobin concentration falls below normal
Decreased oxygen-carrying capacity
Tissue hypoxia develops
Compensatory mechanisms activated:

Increased cardiac output
Increased respiratory rate
Redistribution of blood flow to vital organs
Increased 2,3-DPG production (enhances oxygen release)

2. Megaloblastic Anemia (Vitamin B12/Folate Deficiency)

Mechanism:

Vitamin B12 or folate deficiency impairs DNA synthesis
Thymidine synthesis disrupted
Nuclear maturation delayed while cytoplasmic maturation proceeds normally
Asynchronous cellular development (nuclear-cytoplasmic dissociation)

Cellular Changes:

Bone marrow produces large, immature RBCs (megaloblasts)
Ineffective erythropoiesis (cells die in bone marrow before maturation)
Macrocytic RBCs (MCV >100 fL) released into circulation
Pancytopenia may develop (affects all cell lines)
Hypersegmented neutrophils characteristic finding

Vitamin B12 Deficiency Additional Effects:

Myelin synthesis impaired
Neurological damage occurs:

Demyelination of posterior and lateral spinal columns
Peripheral neuropathy
Subacute combined degeneration

3. Anemia of Chronic Disease

Mechanism:

Chronic inflammation triggers immune response
Increased hepcidin production by liver
Hepcidin blocks iron release from:

Macrophages (recycled iron from old RBCs)
Enterocytes (dietary iron absorption)
Hepatocytes (stored iron)

Consequences:

Functional iron deficiency (adequate stores but unavailable for erythropoiesis)
Decreased EPO production and response
Shortened RBC lifespan (80-90 days instead of 120)
Mild to moderate normocytic, normochromic anemia
Bone marrow shows adequate iron stores but decreased incorporation

4. Aplastic Anemia

Mechanism:

Bone marrow failure due to:

Autoimmune destruction of hematopoietic stem cells
Toxic exposure (benzene, radiation, chemotherapy)
Viral infections (hepatitis, EBV, HIV)
Idiopathic (50-70% of cases)

Consequences:

Pancytopenia (anemia, leukopenia, thrombocytopenia)
Hypocellular bone marrow with fatty replacement
Absence of abnormal cells (distinguishes from leukemia)
Severe complications:

Bleeding (thrombocytopenia)
Infections (neutropenia)
Tissue hypoxia (anemia)

B. Increased RBC Destruction (Hemolytic Anemia)

1. Intravascular Hemolysis

Mechanism:

RBC destruction within blood vessels
Causes: mechanical trauma, complement-mediated lysis, infections

Process:

RBC membrane rupture releases hemoglobin into plasma
Hemoglobin binds to haptoglobin (rapidly depleted)
Free hemoglobin oxidized to methemoglobin
Hemoglobin filtered by kidneys → hemoglobinuria
Iron loss in urine
Hemosiderin deposits in renal tubules (hemosiderinuria)

Consequences:

Hemoglobinemia
Hemoglobinuria (dark/tea-colored urine)
Decreased haptoglobin
Increased lactate dehydrogenase (LDH)
Risk of acute kidney injury

2. Extravascular Hemolysis

Mechanism:

RBCs removed by reticuloendothelial system (spleen, liver)
Causes: antibody coating, membrane defects, enzyme deficiencies

Process:

Abnormal RBCs recognized by macrophages
Phagocytosis in spleen and liver
Hemoglobin catabolism:

Heme → biliverdin → unconjugated bilirubin
Iron recycled or stored
Globin broken down to amino acids

Consequences:

Increased unconjugated (indirect) bilirubin
Jaundice (when bilirubin >2-3 mg/dL)
Increased urobilinogen in urine and stool
Splenomegaly (chronic cases)
Gallstones (pigmented, from excess bilirubin)

Compensatory Response to Hemolysis:

Bone marrow hyperplasia (increased RBC production 6-8 fold)
Reticulocytosis (elevated reticulocyte count)
If compensation inadequate → anemia develops

3. Sickle Cell Anemia (Example of Hemolytic Anemia)

Mechanism:

Genetic mutation: glutamic acid replaced by valine at position 6 of beta-globin chain
Hemoglobin S (HbS) produced instead of normal HbA

Pathological Process:

Deoxygenation: HbS polymerizes when oxygen tension low
Sickling: RBCs assume rigid, crescent shape
Vaso-occlusion: Sickled cells block small blood vessels
Ischemia: Tissue hypoxia and infarction
Hemolysis: Sickled cells fragile, shortened lifespan (10-20 days)

Consequences:

Chronic hemolytic anemia
Painful vaso-occlusive crises
Organ damage (spleen, kidneys, lungs, bones)
Increased infection risk (splenic dysfunction)
Stroke risk
Acute chest syndrome

C. Blood Loss Anemia

1. Acute Blood Loss

Immediate Phase (0-24 hours):

Hemorrhage decreases blood volume
Hypovolemia and hypotension
Compensatory mechanisms:

Vasoconstriction (maintains blood pressure)
Tachycardia (maintains cardiac output)
Activation of renin-angiotensin-aldosterone system
ADH release (fluid retention)

Hemoglobin/hematocrit initially normal (proportional loss of cells and plasma)

Compensatory Phase (24-72 hours):

Fluid shifts from interstitial space to intravascular space
Hemodilution occurs
Hemoglobin and hematocrit decrease
Anemia becomes apparent
Normocytic, normochromic initially

Recovery Phase (3-5 days):

Bone marrow stimulation by EPO
Reticulocytosis (peaks at 7-10 days)
Gradual restoration of RBC mass
If iron deficiency develops → microcytic anemia

2. Chronic Blood Loss

Mechanism:

Persistent, slow bleeding (GI tract, menstruation)
Continuous iron loss exceeds dietary intake and stores

Process:

Initial compensation maintains normal hemoglobin
Gradual iron store depletion
Progression through stages of iron deficiency
Development of iron deficiency anemia
Microcytic, hypochromic RBCs

Consequences:

Insidious onset
Often asymptomatic until moderate to severe
Underlying bleeding source may remain undiagnosed
Chronic tissue hypoxia and adaptation

Compensatory Mechanisms in Anemia

1. Cardiovascular Compensation

Increased cardiac output (stroke volume × heart rate)
Tachycardia at rest and with minimal exertion
Increased blood flow velocity
Preferential blood flow to vital organs (brain, heart)
Peripheral vasoconstriction
May lead to high-output heart failure in severe chronic anemia

2. Respiratory Compensation

Increased respiratory rate
Increased depth of breathing
Enhanced oxygen extraction at tissue level
Dyspnea on exertion

3. Hematological Compensation

Increased EPO production (up to 1000-fold in severe anemia)
Bone marrow hyperplasia
Increased RBC production (reticulocytosis)
Shift of oxygen-hemoglobin dissociation curve to right (increased 2,3-DPG)
Enhanced oxygen release to tissues

4. Tissue-Level Adaptations

Increased capillary density
Enhanced oxygen extraction
Shift to anaerobic metabolism (lactic acidosis in severe cases)

Consequences of Tissue Hypoxia

Acute Severe Anemia:

Decreased oxygen delivery to tissues
Lactic acidosis
End-organ dysfunction
Myocardial ischemia
Altered mental status
Potential for cardiovascular collapse

Chronic Anemia:

Fatigue and weakness
Impaired cognitive function
Decreased exercise tolerance
Growth retardation in children
Immune dysfunction
Delayed wound healing
Koilonychia (spoon-shaped nails) in iron deficiency
Glossitis and angular stomatitis (nutritional deficiencies)

┌─────────────────────────────────────────────────────────────────┐

│ ETIOLOGY OF ANEMIA │

└────────────┬────────────────────────────────────┬─────────────────┘

│ │

┌────────▼─────────┐ ┌──────────▼──────────┐

│ DECREASED RBC │ │ INCREASED RBC │

│ PRODUCTION │ │ DESTRUCTION │

└────────┬─────────┘ └──────────┬──────────┘

│ │

┌────────▼────────────────────┐ ┌─────────▼──────────────┐

│ • Iron deficiency │ │ • Hemolytic anemia │

│ • Vitamin B12/Folate ↓ │ │ • Sickle cell disease │

│ • Bone marrow failure │ │ • Autoimmune hemolysis │

│ • Chronic kidney disease │ │ • G6PD deficiency │

│ • Anemia of chronic disease │ │ • Thalassemia │

└────────┬────────────────────┘ └─────────┬──────────────┘

│ │

│ ┌──────────────────┘

│ │

┌────────▼─────────────────▼──────┐

│ Decreased Hemoglobin/RBC Count │

└────────┬─────────────────────────┘

│

┌────────▼────────────────────────────┐

│ REDUCED OXYGEN-CARRYING CAPACITY │

└────────┬────────────────────────────┘

│

┌────────▼─────────────────┐

│ TISSUE HYPOXIA │

└────────┬─────────────────┘

│

┌────────▼──────────────────────────────────┐

│ COMPENSATORY MECHANISMS │

│ • ↑ Cardiac output (tachycardia) │

│ • ↑ Respiratory rate │

│ • ↑ EPO production → ↑ erythropoiesis │

│ • ↑ 2,3-DPG (enhanced O₂ release) │

│ • Blood redistribution to vital organs │

└────────┬──────────────────────────────────┘

│

┌────────▼─────────────────────────────────────┐

│ COMPENSATION ADEQUATE? │

└────┬─────────────────────────────────┬───────┘

│ YES │ NO

│ │

┌────▼──────────────┐ ┌──────────▼─────────────────┐

│ Asymptomatic or │ │ CLINICAL MANIFESTATIONS │

│ Mild symptoms │ │ • Fatigue, weakness │

└───────────────────┘ │ • Pallor │

│ • Dyspnea │

│ • Tachycardia │

│ • Palpitations │

│ • Dizziness │

└──────────┬─────────────────┘

│

┌──────────▼─────────────────┐

│ PROGRESSION IF UNTREATED │

│ • Heart failure │

│ • Cognitive impairment │

│ • Organ dysfunction │

│ • Death (severe cases) │

└────────────────────────────┘

┌──────────────────────────────────────────────────────────────┐

│ BLOOD LOSS PATHWAY │

└────────────┬───────────────────────────────────────────────────┘

│

┌────────▼──────────┐

│ ACUTE BLOOD │

│ LOSS │

└────────┬──────────┘

│

┌────────▼──────────────────────┐

│ • Trauma/Surgery │

│ • GI bleeding │

│ • Ruptured aneurysm │

└────────┬──────────────────────┘

│

┌────────▼─────────────────────┐ ┌──────────────────┐

│ HYPOVOLEMIA │ │ CHRONIC BLOOD │

│ • ↓ Blood pressure │ │ LOSS │

│ • ↓ Tissue perfusion │ └────────┬─────────┘

│ • Shock (if severe) │ │

└──────────────────────────────┘ ┌────────▼─────────┐

│ • Menorrhagia │

│ • GI bleeding │

│ • Hookworm │

└────────┬─────────┘

│

┌────────▼─────────┐

│ IRON DEPLETION │

│ → Iron deficiency│

│ anemia │

└──────────────────┘

Above Diagram generated By AI

5. CLINICAL MANIFESTATIONS

Anemia presents with a wide spectrum of clinical features that vary based on the severity, rate of onset, underlying cause, and individual patient factors such as age and comorbidities.

Signs (Objective Findings)

A. General Appearance

Pallor (most common sign)

Conjunctival pallor (highly specific when present)
Palmar pallor (pale palmar creases)
Pale nail beds
Pale mucous membranes (oral cavity, tongue)
Pale skin (best assessed in natural light)

Vital Signs Abnormalities

Tachycardia (resting heart rate >100 bpm)
Tachypnea (respiratory rate >20 breaths/min)
Hypotension (in acute severe blood loss)
Postural hypotension (orthostatic changes)
Widened pulse pressure (chronic severe anemia)

B. Cardiovascular Signs

Flow murmur (systolic ejection murmur, especially at apex)
Prominent apical impulse
S3 gallop (heart failure in severe anemia)
Jugular venous distension (if heart failure develops)
Peripheral edema (heart failure)
Bounding pulses (high-output state)

C. Respiratory Signs

Dyspnea at rest or on exertion
Increased work of breathing
Use of accessory muscles

D. Integumentary Signs

Iron Deficiency Specific:

Koilonychia (spoon-shaped nails)
Brittle nails
Hair loss or thinning
Dry, rough skin
Angular stomatitis (cracks at corners of mouth)
Glossitis (smooth, red, painful tongue)
Atrophic glossitis (loss of papillae)

Hemolytic Anemia Specific:

Jaundice (icterus) - yellowish discoloration of skin and sclera
Splenomegaly (enlarged spleen on palpation)
Hepatomegaly (enlarged liver)
Dark urine (hemoglobinuria in intravascular hemolysis)

Vitamin B12 Deficiency Specific:

Lemon-yellow tint to skin (combination of pallor and mild jaundice)
Glossitis with beefy red tongue
Neurological signs (see below)

E. Neurological Signs (Particularly in Vitamin B12 Deficiency)

Decreased vibration sense (posterior column involvement)
Decreased proprioception
Positive Romberg test
Ataxia (unsteady gait)
Decreased deep tendon reflexes
Positive Babinski sign
Cognitive impairment or confusion
Peripheral neuropathy (glove and stocking distribution)
Paresthesias

F. Hematological Signs

Petechiae or purpura (if associated thrombocytopenia)
Bleeding tendency (easy bruising)
Lymphadenopathy (in some hemolytic anemias or underlying malignancy)

G. Specific Syndrome Signs

Plummer-Vinson Syndrome (severe iron deficiency):

Esophageal webs
Dysphagia
Glossitis
Angular stomatitis

Sickle Cell Disease:

Dactylitis (hand-foot syndrome in children)
Leg ulcers
Priapism
Joint swelling

Symptoms (Subjective Findings)

A. General Symptoms

Fatigue (most common symptom)

Persistent tiredness
Lack of energy
Easily exhausted with minimal activity

Weakness

Generalized body weakness
Muscle weakness
Reduced stamina

Malaise (general feeling of discomfort)
Decreased exercise tolerance
Lethargy and drowsiness

B. Cardiovascular Symptoms

Palpitations (awareness of heartbeat)
Chest pain (angina, especially in elderly or those with coronary artery disease)
Shortness of breath (dyspnea)

Dyspnea on exertion initially
Dyspnea at rest in severe cases

Orthopnea (difficulty breathing when lying flat)

C. Neurological Symptoms

Headache (often frontal)
Dizziness or lightheadedness
Vertigo (spinning sensation)
Syncope or near-syncope (fainting)
Tinnitus (ringing in ears)
Difficulty concentrating
Memory impairment
Confusion or altered mental status (severe anemia)
Irritability and mood changes
Restless legs syndrome
Paresthesias (numbness, tingling in hands and feet - B12 deficiency)

D. Gastrointestinal Symptoms

Anorexia (loss of appetite)
Nausea
Sore tongue (glossodynia)
Difficulty swallowing (dysphagia - Plummer-Vinson syndrome)
Pica (craving for non-food items):

Pagophagia (ice craving - highly specific for iron deficiency)
Clay, dirt, starch, paper

Altered taste (dysgeusia)
Indigestion

E. Genitourinary Symptoms

Decreased libido
Menstrual irregularities
Dark or cola-colored urine (hemoglobinuria in hemolytic anemia)

F. Musculoskeletal Symptoms

Bone pain (in hemolytic anemias with marrow hyperplasia)
Joint pain
Muscle cramps

G. Visual Symptoms

Blurred vision
Scotomas (spots in visual field)
Diplopia (double vision)

H. Cold Intolerance

Sensitivity to cold
Cold hands and feet

Severity-Based Presentation

Mild Anemia (Hb: 10-12 g/dL in women; 10-13 g/dL in men)

Often asymptomatic
Fatigue with strenuous activity
Mild pallor may be present
Most patients adapt well

Moderate Anemia (Hb: 8-10 g/dL)

Fatigue with moderate activity
Dyspnea on exertion
Palpitations
Noticeable pallor
Headaches
Dizziness

Severe Anemia (Hb: 6.5-8 g/dL)

Fatigue at rest
Significant dyspnea
Tachycardia
Chest pain
Severe weakness
Confusion or cognitive impairment
High-output heart failure risk

Life-Threatening Anemia (Hb <6.5 g/dL)

Severe dyspnea at rest
Altered mental status
Syncope
Congestive heart failure
Shock (if acute)
Myocardial ischemia
Risk of death without urgent treatment

Acute vs. Chronic Presentation

Acute Anemia (rapid onset, e.g., hemorrhage):

Symptoms prominent even with mild decrease in Hb
Hypovolemic symptoms predominate
Tachycardia, hypotension
Dizziness, syncope
Shock if severe
Little time for compensation

Chronic Anemia (gradual onset):

Patients often asymptomatic until Hb significantly reduced
Better compensation by cardiovascular and respiratory systems
Symptoms develop insidiously
May tolerate very low Hb levels
Symptoms mainly related to tissue hypoxia

6. DIAGNOSTIC EVALUATION

Comprehensive diagnostic evaluation is essential to confirm the presence of anemia, determine its severity, identify the underlying cause, and guide appropriate management.

Laboratory Investigations

A. Complete Blood Count (CBC) - First-Line Test

Hemoglobin (Hb)

Normal values:

Adult males: 13.5-17.5 g/dL
Adult females: 12.0-15.5 g/dL
Pregnant women: >11 g/dL

Interpretation: Decreased in anemia; degree of reduction indicates severity

Hematocrit (Hct)

Normal values:

Adult males: 39-49%
Adult females: 35-45%

Interpretation: Percentage of blood volume occupied by RBCs; reduced in anemia

Red Blood Cell (RBC) Count

Normal values:

Adult males: 4.5-5.5 million/μL
Adult females: 4.0-5.0 million/μL

Interpretation: Absolute number of RBCs; decreased in anemia

Red Cell Indices (help classify anemia type)

Mean Corpuscular Volume (MCV)

Normal: 80-100 fL
Interpretation:

Microcytic (MCV <80 fL): Iron deficiency, thalassemia, anemia of chronic disease (some cases), lead poisoning, sideroblastic anemia
Normocytic (MCV 80-100 fL): Acute blood loss, hemolytic anemia, aplastic anemia, chronic kidney disease, anemia of chronic disease
Macrocytic (MCV >100 fL): Vitamin B12 deficiency, folate deficiency, liver disease, hypothyroidism, myelodysplastic syndromes, alcohol abuse

Mean Corpuscular Hemoglobin (MCH)

Normal: 27-31 pg
Interpretation: Average weight of hemoglobin per RBC; parallels MCV changes

Mean Corpuscular Hemoglobin Concentration (MCHC)

Normal: 32-36 g/dL
Interpretation:

Decreased (hypochromic): Iron deficiency, thalassemia
Normal (normochromic): Most other anemias
Increased: Spherocytosis, severe burns

Red Cell Distribution Width (RDW)

Normal: 11.5-14.5%
Interpretation:

Increased: Indicates variation in RBC size (anisocytosis)
Helpful in differentiating causes:

Iron deficiency: High RDW
Thalassemia trait: Normal RDW
Mixed anemias: High RDW

Reticulocyte Count

Normal: 0.5-2.5% of RBCs (or 25,000-75,000/μL)
Interpretation:

Elevated (>2.5%): Indicates active bone marrow response; seen in hemolytic anemia, acute blood loss, response to treatment
Low or normal (<2%): Inadequate bone marrow response; seen in iron deficiency, B12/folate deficiency, aplastic anemia, bone marrow disorders

Corrected Reticulocyte Count:

Formula: (Patient's Hct / Normal Hct) × Reticulocyte %
Better assessment of bone marrow response

White Blood Cell (WBC) Count and Differential

Purpose: Identify associated conditions
Findings:

Leukopenia: Aplastic anemia, megaloblastic anemia
Leukocytosis: Hemolytic anemia, acute blood loss, infection, leukemia

Platelet Count

Normal: 150,000-400,000/μL
Interpretation:

Thrombocytopenia: Aplastic anemia, megaloblastic anemia, bone marrow infiltration
Thrombocytosis: Iron deficiency (reactive), chronic bleeding, hemolysis

B. Peripheral Blood Smear (PBS)

Morphological Examination:

RBC Morphology:

Microcytic, hypochromic cells: Iron deficiency
Macrocytic, oval cells (macro-ovalocytes): Megaloblastic anemia
Sickle cells: Sickle cell disease
Spherocytes: Hereditary spherocytosis, autoimmune hemolytic anemia
Schistocytes (fragmented RBCs): Microangiopathic hemolytic anemia, mechanical hemolysis
Target cells: Thalassemia, liver disease, hemoglobin C disease
Howell-Jolly bodies: Post-splenectomy, severe hemolysis, megaloblastic anemia
Basophilic stippling: Lead poisoning, thalassemia
Rouleaux formation: Multiple myeloma, chronic inflammation

WBC Morphology:

Hypersegmented neutrophils (>5 lobes): Megaloblastic anemia (pathognomonic)

Platelet Morphology:

Size, number, clumping

C. Iron Studies

Serum Iron

Normal: 60-170 μg/dL
Interpretation:

Decreased: Iron deficiency anemia
Increased: Hemolytic anemia, iron overload, sideroblastic anemia

Total Iron-Binding Capacity (TIBC)

Normal: 240-450 μg/dL
Interpretation:

Increased: Iron deficiency anemia (>450 μg/dL)
Decreased: Anemia of chronic disease, hemolytic anemia

Transferrin Saturation

Calculation: (Serum Iron / TIBC) × 100
Normal: 20-50%
Interpretation:

<15%: Iron deficiency anemia
50%: Iron overload, hemolytic anemia

Serum Ferritin

Normal:

Males: 20-250 ng/mL
Females: 10-120 ng/mL

Interpretation:

<30 ng/mL: Iron deficiency (diagnostic)
<15 ng/mL: Definite iron deficiency
Normal or elevated: Anemia of chronic disease (ferritin is an acute-phase reactant)
1000 ng/mL: Iron overload

Most specific test for iron deficiency

Soluble Transferrin Receptor (sTfR)

Use: Differentiates iron deficiency from anemia of chronic disease
Interpretation:

Elevated: Iron deficiency
Normal: Anemia of chronic disease

D. Vitamin Studies

Serum Vitamin B12 (Cobalamin)

Normal: 200-900 pg/mL
Interpretation:

<200 pg/mL: Deficiency
200-300 pg/mL: Borderline; check methylmalonic acid

Serum Folate

Normal: 2-20 ng/mL
Interpretation:

<2 ng/mL: Deficiency

Red Cell Folate

Normal: 140-960 ng/mL
Interpretation: More accurate than serum folate; reflects tissue stores

Serum Methylmalonic Acid (MMA)

Normal: <0.4 μmol/L
Interpretation:

Elevated: B12 deficiency (sensitive and specific)
Normal in folate deficiency

Serum Homocysteine

Normal: 5-15 μmol/L
Interpretation:

Elevated: Both B12 and folate deficiency (not specific)

E. Hemolysis Panel (if hemolytic anemia suspected)

Indirect (Unconjugated) Bilirubin

Normal: <1.0 mg/dL
Interpretation: Elevated in hemolysis (>1.0 mg/dL)

Lactate Dehydrogenase (LDH)

Normal: 140-280 U/L
Interpretation: Markedly elevated in hemolysis (>1000 U/L common)

Serum Haptoglobin

Normal: 30-200 mg/dL
Interpretation:

Decreased or absent (<30 mg/dL): Intravascular hemolysis
Normal: Does not exclude extravascular hemolysis

Direct Antiglobulin Test (DAT/Direct Coombs Test)

Purpose: Detects antibodies or complement on RBC surface
Interpretation:

Positive: Autoimmune hemolytic anemia, drug-induced hemolysis, transfusion reaction
Negative: Hereditary hemolytic anemias, other causes

Urinalysis

Hemoglobinuria: Dark/tea-colored urine in intravascular hemolysis
Urobilinogen: Increased in hemolysis
Hemosiderin: Chronic intravascular hemolysis

F. Specialized Tests

Hemoglobin Electrophoresis

Purpose: Identify abnormal hemoglobins
Indications: Suspected hemoglobinopathies (sickle cell, thalassemia)
Findings:

HbS: Sickle cell disease
HbC, HbE: Other hemoglobinopathies
Elevated HbA2, HbF: Thalassemia

G6PD Enzyme Assay

Purpose: Diagnose glucose-6-phosphate dehydrogenase deficiency
Timing: Should be done when patient not actively hemolyzing (false negative)

Osmotic Fragility Test

Purpose: Diagnose hereditary spherocytosis
Interpretation: Increased fragility indicates spherocytosis

Schilling Test

Purpose: Determine cause of B12 deficiency (rarely performed now)
Stages: Differentiates pernicious anemia from malabsorption

Intrinsic Factor Antibodies

Purpose: Diagnose pernicious anemia
Interpretation: Positive in 50-70% of pernicious anemia cases

Parietal Cell Antibodies

Purpose: Screen for autoimmune gastritis
Interpretation: Positive in 85-90% of pernicious anemia

Erythropoietin (EPO) Level

Purpose: Evaluate anemia in chronic kidney disease
Normal: 4-26 mU/mL
Interpretation:

Inappropriately low: Chronic kidney disease
Elevated: Appropriate response to anemia

Lead Level

Indication: Suspected lead poisoning
Normal: <10 μg/dL
Interpretation: >10 μg/dL indicates lead toxicity

G. Bone Marrow Examination

Indications:

Unexplained anemia after initial workup
Suspected aplastic anemia
Suspected leukemia or myelodysplastic syndrome
Suspected bone marrow infiltration (cancer)
Pancytopenia

Procedures:

Bone Marrow Aspiration:

Examines cellular morphology and maturation
Assesses iron stores (Prussian blue stain)

Bone Marrow Biopsy:

Evaluates marrow cellularity
Identifies fibrosis, infiltration
Assesses architecture

Findings:

Iron deficiency: Absent iron stores
Megaloblastic anemia: Megaloblastic changes, hypersegmented neutrophils
Aplastic anemia: Hypocellular marrow with fatty replacement
Hemolytic anemia: Erythroid hyperplasia
Leukemia: Blast cells, abnormal cells
Myelodysplasia: Dysplastic changes

Imaging Studies

A. Chest X-ray

Purpose: Evaluate cardiac size, pulmonary congestion
Findings:

Cardiomegaly (heart failure from severe chronic anemia)
Pulmonary edema

B. Abdominal Ultrasound

Purpose: Assess spleen and liver size
Findings:

Splenomegaly (hemolytic anemia, thalassemia)
Hepatomegaly (hemolytic anemia, liver disease)

C. Upper GI Endoscopy (Esophagogastroduodenoscopy - EGD)

Indication: Suspected upper GI bleeding
Findings:

Peptic ulcers
Gastritis
Esophageal varices
Malignancy
Celiac disease (duodenal biopsy)

D. Colonoscopy

Indication: Suspected lower GI bleeding, especially in adults >50 years
Findings:

Colorectal cancer
Polyps
Inflammatory bowel disease
Angiodysplasia
Hemorrhoids

E. Capsule Endoscopy

Indication: Obscure GI bleeding when EGD and colonoscopy negative
Purpose: Visualize small bowel

F. CT Scan or MRI Abdomen

Purpose: Evaluate for malignancy, lymphadenopathy, organomegaly
Indication: Suspected occult malignancy or chronic disease

G. Skull/Long Bone X-rays

Indication: Thalassemia major, sickle cell disease
Findings:

"Hair-on-end" appearance of skull (marrow hyperplasia)
Bone infarcts in sickle cell disease

Diagnostic Procedures

A. Stool Examination

Fecal Occult Blood Test (FOBT)

Purpose: Detect occult GI bleeding
Types: Guaiac-based, immunochemical
Interpretation: Positive suggests GI blood loss

Stool for Ova and Parasites

Purpose: Identify parasitic infections (hookworm, whipworm)
Indication: Endemic areas, unexplained iron deficiency

B. Genetic Testing

Indications: Suspected inherited anemias
Tests:

Sickle cell gene testing
Thalassemia gene analysis
Hereditary spherocytosis gene mutations
Other rare hemoglobinopathies

C. Urine Tests

24-hour Urine Hemosiderin

Purpose: Detect chronic intravascular hemolysis
Positive: Hemoglobinuria episodes

Urine Protein Electrophoresis

Purpose: Detect monoclonal protein (multiple myeloma)

7. MEDICAL MANAGEMENT

Management of anemia is directed at treating the underlying cause, correcting the hemoglobin deficiency, preventing complications, and improving quality of life.

Medications

A. Iron Supplementation (for Iron Deficiency Anemia)

1. Oral Iron Preparations

Ferrous Salts (First-Line):

Ferrous Sulfate: 325 mg tablets (65 mg elemental iron)

Dosage: 325 mg PO TID (total 195 mg elemental iron daily)
Most commonly prescribed, inexpensive

Ferrous Gluconate: 325 mg tablets (36 mg elemental iron)

Dosage: 325 mg PO TID
Better tolerated, less GI side effects

Ferrous Fumarate: 325 mg tablets (106 mg elemental iron)

Dosage: 325 mg PO once to twice daily
Highest elemental iron content

Administration Guidelines:

Take on empty stomach (1 hour before or 2 hours after meals) for maximum absorption
If GI upset occurs, may take with food (reduces absorption by 40-50%)
Avoid taking with:

Dairy products (calcium inhibits absorption)
Tea, coffee (tannins inhibit absorption)
Antacids, proton pump inhibitors
Calcium supplements
Tetracycline antibiotics

Enhancing Absorption:

Take with vitamin C (orange juice, ascorbic acid 250 mg)
Separate from other medications by 2 hours

Expected Response:

Reticulocytosis in 5-10 days
Hemoglobin increase of 1 g/dL every 2-3 weeks
Continue for 3-6 months after hemoglobin normalized (replenish stores)

Side Effects:

Gastrointestinal: Nausea, constipation, diarrhea, abdominal pain, dark stools (30-40% of patients)
Teeth staining (liquid formulations)
Management: Reduce dose, take with food, switch formulations, use stool softeners

Contraindications:

Hemochromatosis
Hemosiderosis
Hemolytic anemia (unless concurrent iron deficiency)

2. Parenteral Iron (IV/IM)

Indications:

Intolerance to oral iron
Malabsorption (celiac disease, inflammatory bowel disease, gastric bypass)
Ongoing blood losses exceeding oral replacement
Chronic kidney disease on erythropoietin
Severe anemia requiring rapid correction
Non-compliance with oral therapy

Preparations:

Iron Sucrose (Venofer):

Dosage: 200 mg IV over 2-5 minutes or diluted infusion
Total dose given in divided doses over weeks

Ferric Gluconate (Ferrlecit):

Dosage: 125 mg IV over 1 hour
Repeat doses as needed

Iron Dextran (INFeD, DexFerrum):

High molecular weight and low molecular weight forms
Test dose required (25 mg IV) due to anaphylaxis risk (0.6%)
Can give total dose infusion

Ferric Carboxymaltose (Injectafer):

Dosage: 750 mg IV over 15 minutes
Can give up to 1500 mg per week
No test dose needed

Ferumoxytol (Feraheme):

Dosage: 510 mg IV over 17 seconds
Repeat in 3-8 days
No test dose needed

Administration:

Monitor vital signs during infusion
Resuscitation equipment available
Observe for 30-60 minutes post-infusion

Side Effects:

Hypersensitivity reactions (anaphylaxis with iron dextran)
Hypotension
Flushing
Arthralgia, myalgia
Headache
Injection site reactions (IM)
Staining of skin (IM Z-track technique required)

Advantages:

Rapid iron repletion
Bypasses GI absorption issues
Better compliance

B. Vitamin B12 (Cobalamin) Supplementation

Indications:

Pernicious anemia
Malabsorption syndromes
Strict vegetarian/vegan diet
Post-gastrectomy
Terminal ileum disease/resection

1. Parenteral Vitamin B12

Cyanocobalamin (most common) or Hydroxocobalamin:

Dosage Regimen (Pernicious Anemia):

Loading Phase: 1000 μg IM daily for 1 week
Continuation: 1000 μg IM weekly for 4 weeks
Maintenance: 1000 μg IM monthly for life

For Dietary Deficiency:

May use oral supplementation if absorption intact
1000-2000 μg PO daily

2. Oral Vitamin B12

High-Dose Oral Therapy:

Dosage: 1000-2000 μg daily
Mechanism: Passive absorption (1-2% absorbed even without intrinsic factor)
Indication: Mild deficiency, dietary insufficiency, patient preference
Efficacy: Comparable to IM in compliant patients

3. Intranasal/Sublingual Formulations

Dosage: 500 μg weekly (intranasal)
Alternative for patients refusing injections
Less studied than oral or IM routes

Expected Response:

Reticulocytosis peaks at 7-10 days
Neurological symptoms improve within weeks (if present <6 months)
Hemoglobin normalizes in 1-2 months
Complete blood count normalization in 2 months

Monitoring:

Hemoglobin every 2-4 weeks until normalized
B12 levels at 1 month, then annually
Methylmalonic acid if neurological symptoms persist

C. Folic Acid Supplementation

Indications:

Folate deficiency anemia
Pregnancy (prevention of neural tube defects)
Chronic hemolytic anemias (increased demand)
Malabsorption
Alcoholism
Medications interfering with folate metabolism (methotrexate, phenytoin)

Dosage:

Treatment: 1-5 mg PO daily for 1-4 months
Pregnancy prophylaxis: 400-800 μg daily (0.4-0.8 mg)
High-risk pregnancy: 4-5 mg daily
Maintenance (chronic hemolysis): 1 mg daily

Administration:

Can be taken with or without food
Well absorbed orally even in malabsorption (usually)

Expected Response:

Reticulocytosis in 3-5 days
Hemoglobin increases by 1-2 g/dL per week
Normalization in 1-2 months

Important Precaution:

Never give folate alone if B12 deficiency not excluded
Folate can correct anemia but worsen neurological complications of B12 deficiency
Always check B12 level before starting folate

D. Erythropoiesis-Stimulating Agents (ESAs)

Indications:

Anemia of chronic kidney disease (CKD)
Chemotherapy-induced anemia in cancer patients
Anemia in HIV patients on zidovudine
Reduction of transfusion in perioperative period (selected cases)

Agents:

1. Epoetin Alfa (Epogen, Procrit)

Mechanism: Recombinant human erythropoietin
Dosage (CKD):

Initial: 50-100 units/kg SC/IV 3 times weekly
Adjust dose to maintain Hb 10-12 g/dL (not >11 g/dL)

2. Darbepoetin Alfa (Aranesp)

Mechanism: Long-acting ESA
Dosage: 0.45 μg/kg SC/IV once weekly or 0.75 μg/kg every 2 weeks
Advantage: Less frequent dosing

3. Methoxy Polyethylene Glycol-Epoetin Beta (Mircera)

Mechanism: Continuous erythropoietin receptor activator
Dosage: Once every 2-4 weeks
Advantage: Longest duration of action

Administration Guidelines:

Subcutaneous route preferred (better efficacy, lower dose)
IV route in hemodialysis patients
Rotate injection sites
Ensure adequate iron stores before initiating (ferritin >100 ng/mL, transferrin saturation >20%)
Supplement iron if needed

Monitoring:

Hemoglobin weekly initially, then monthly once stable
Blood pressure (risk of hypertension)
Iron studies every 1-3 months
Adjust dose to maintain Hb 10-12 g/dL

Target Hemoglobin:

CKD: 10-11.5 g/dL
Cancer: Lowest level to avoid transfusion (not >12 g/dL)
Avoid Hb >12 g/dL (increased cardiovascular events, thrombosis, mortality)

Side Effects:

Hypertension (monitor BP closely)
Thrombosis (stroke, MI, DVT, clotted vascular access)
Headache
Flu-like symptoms
Pure red cell aplasia (rare, from antibodies to EPO)
Seizures (rare)

Contraindications:

Uncontrolled hypertension
Pure red cell aplasia
Hypersensitivity

Black Box Warning:

Increased mortality, cardiovascular events, and tumor progression when targeting higher Hb levels
Use lowest dose to avoid transfusions

E. Immunosuppressive Therapy (for Aplastic Anemia)

Indications:

Aplastic anemia (if not candidate for bone marrow transplant)
Autoimmune hemolytic anemia

Agents:

1. Antithymocyte Globulin (ATG)

Horse ATG (ATGAM): 40 mg/kg/day IV for 4 days
Rabbit ATG (Thymoglobulin): 3.5 mg/kg/day IV for 5 days
Mechanism: Suppresses T-cell mediated destruction of hematopoietic stem cells

2. Cyclosporine

Dosage: 5-10 mg/kg/day PO divided BID
Mechanism: Calcineurin inhibitor; immunosuppressive
Use: Combined with ATG; maintenance therapy
Monitoring: Trough levels, renal function

3. Corticosteroids

Indication: Autoimmune hemolytic anemia, ITP
Prednisone: 1 mg/kg/day PO initially, taper over weeks to months
Mechanism: Suppresses antibody production and macrophage function

Response:

May take 3-6 months to see improvement
Monitor blood counts weekly initially

F. Chelating Agents (for Iron Overload)

Indications:

Transfusion-dependent anemias (thalassemia major, sickle cell disease)
Hereditary hemochromatosis

Agents:

1. Deferoxamine (Desferal)

Dosage: 20-40 mg/kg/day SC or IV infusion over 8-12 hours, 5-7 days per week
Mechanism: Chelates iron for urinary excretion

2. Deferasirox (Exjade, Jadenu)

Dosage: 20-40 mg/kg PO once daily
Advantage: Oral administration, once daily
Monitoring: Renal and hepatic function

3. Deferiprone (Ferriprox)

Dosage: 75-100 mg/kg/day PO divided TID
Advantage: Crosses blood-brain barrier, cardiac iron removal
Side Effect: Agranulocytosis (monitor ANC weekly)

Monitoring:

Serum ferritin every 1-3 months (goal <1000 ng/mL)
Liver and renal function tests
Cardiac MRI T2* (assess cardiac iron)

G. Other Medications

1. Hydroxyurea (Sickle Cell Disease)

Dosage: 15-35 mg/kg/day PO
Mechanism: Increases HbF, reduces sickling
Benefits: Reduces pain crises, acute chest syndrome, need for transfusions
Monitoring: CBC every 2-4 weeks

2. L-Glutamine (Endari) - Sickle Cell Disease

Dosage: 5-15 grams PO BID
Mechanism: Reduces oxidative stress
Benefits: Reduces pain crises

3. Voxelotor (Oxbryta) - Sickle Cell Disease

Dosage: 1500 mg PO once daily
Mechanism: Increases Hb oxygen affinity, prevents sickling
Benefits: Increases hemoglobin, reduces hemolysis

4. Crizanlizumab (Adakveo) - Sickle Cell Disease

Dosage: 5 mg/kg IV infusion monthly
Mechanism: Monoclonal antibody blocks P-selectin
Benefits: Reduces vaso-occlusive crises

Surgical Management

A. Blood Transfusion

Indications:

Acute severe anemia (Hb <7 g/dL with symptoms or hemodynamic instability)
Symptomatic anemia (chest pain, dyspnea, altered mental status regardless of Hb)
Acute blood loss (>30% blood volume)
Preoperative optimization (Hb <8 g/dL in cardiac surgery)
Severe chronic anemia unresponsive to treatment

Transfusion Thresholds:

General hospitalized patients: Hb <7 g/dL (restrictive strategy)
Patients with cardiovascular disease: Hb <8 g/dL
Acute coronary syndrome: Hb <8-10 g/dL
Symptomatic patients: Higher thresholds may be appropriate

Types:

1. Packed Red Blood Cells (PRBCs)

Volume: 250-350 mL per unit
Expected Hb increase: 1 g/dL per unit (in 70 kg adult)
Dosage: 1-2 units initially, reassess
Administration:

Through blood filter
Over 1-4 hours per unit (slower in heart failure)
Can be rapid in acute hemorrhage

Compatibility: ABO and Rh matched, crossmatched

2. Washed RBCs

Indication: IgA deficiency, severe allergic transfusion reactions
Process: Plasma proteins removed

3. Irradiated RBCs

Indication: Immunocompromised patients, prevent transfusion-associated GVHD
Process: Gamma irradiation destroys donor lymphocytes

4. Leukocyte-Reduced (Leukodepleted) RBCs

Indication: Reduce febrile reactions, CMV transmission, HLA alloimmunization
Standard in many countries

Pre-Transfusion:

Informed consent
Blood type and crossmatch
Baseline vital signs
Verify patient identification and blood product (two-person check)
Large-bore IV access (18-20 gauge)

Monitoring During Transfusion:

Vital signs: Baseline, 15 minutes after start, then hourly
Observe for transfusion reactions
Slow or stop if reaction occurs

Complications:

Acute (within 24 hours):

Acute Hemolytic Transfusion Reaction (AHTR)

ABO incompatibility (clerical error most common cause)
Symptoms: Fever, chills, back pain, dyspnea, hypotension, hemoglobinuria
Management: Stop transfusion immediately, supportive care, maintain renal perfusion

Febrile Non-Hemolytic Transfusion Reaction (FNHTR)

Most common reaction (1-2%)
Symptoms: Fever (>1°C rise), chills
Management: Acetaminophen, slow transfusion; use leukoreduced blood for future

Allergic Reactions

Mild: Urticaria, itching (1-3%)
Treatment: Antihistamines, slow transfusion
Severe: Anaphylaxis (rare)
Treatment: Epinephrine, stop transfusion

Transfusion-Related Acute Lung Injury (TRALI)

Acute respiratory distress within 6 hours
Non-cardiogenic pulmonary edema
Management: Respiratory support, stop transfusion

Transfusion-Associated Circulatory Overload (TACO)

Congestive heart failure from volume overload
Symptoms: Dyspnea, hypertension, pulmonary edema
Management: Diuretics, oxygen, slow transfusion rate

Bacterial Contamination

Rare but serious
Symptoms: High fever, rigors, shock
Management: Stop transfusion, antibiotics, cultures

Delayed (>24 hours):

Delayed Hemolytic Transfusion Reaction

2-10 days post-transfusion
Anamnestic antibody response
Symptoms: Fever, jaundice, decreased Hb

Transfusion-Associated Graft-Versus-Host Disease

Rare, often fatal
Donor lymphocytes attack recipient tissues
Prevention: Irradiated blood in immunocompromised

Iron Overload

After multiple transfusions (>20 units lifetime)
Affects heart, liver, endocrine organs
Management: Iron chelation therapy

Infectious Disease Transmission

Rare due to screening
Viruses: HIV, HBV, HCV (risk <1 in 1,000,000)
Others: Cytomegalovirus, HTLV, malaria, Chagas disease

B. Splenectomy

Indications:

Hereditary spherocytosis: Curative for anemia
Autoimmune hemolytic anemia: Refractory to medical therapy
Thalassemia: Massive splenomegaly, hypersplenism
ITP: Refractory thrombocytopenia

Types:

Open splenectomy: Laparotomy
Laparoscopic splenectomy: Preferred (less morbidity, faster recovery)

Pre-Operative Management:

Vaccinations (2 weeks before surgery if possible):

Pneumococcal (Prevnar 13, Pneumovax 23)
Meningococcal (Menactra, Menveo)
Haemophilus influenzae type B (Hib)

Optimize hematologic status
Transfuse if needed

Post-Operative Complications:

Overwhelming post-splenectomy infection (OPSI):

Lifelong risk (1-2% lifetime)
Encapsulated bacteria (Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae)
High mortality (50%)
Prevention: Vaccination, prophylactic antibiotics, patient education

Thrombocytosis: Platelet count may rise significantly

Risk of thrombosis
May require antiplatelet therapy or anticoagulation

Surgical complications: Bleeding, infection, injury to adjacent organs

Post-Splenectomy Care:

Prophylactic antibiotics:

Penicillin VK 250 mg PO BID or amoxicillin 250 mg PO daily
Lifelong in children, at least 2 years in adults (some recommend lifelong)

Fever protocol: Any fever >38.5°C (101.3°F) is medical emergency

Seek immediate medical attention
Empiric broad-spectrum antibiotics (ceftriaxone)

Vaccination boosters: Per CDC schedule
Medical alert bracelet
Travel precautions: Avoid malaria-endemic areas

C. Bone Marrow/Stem Cell Transplantation

Indications:

Aplastic anemia: Severe, in young patients with matched donor
Thalassemia major: Curative
Sickle cell disease: Curative (selected severe cases)
Myelodysplastic syndromes
Leukemia

Types:

Allogeneic Transplant:

Donor stem cells (sibling, matched unrelated donor, cord blood)
Best option for aplastic anemia, thalassemia
Risk: Graft-versus-host disease (GVHD)

Autologous Transplant:

Patient's own stem cells
Used in certain malignancies

Procedure:

Conditioning regimen: High-dose chemotherapy ± radiation (destroys marrow)
Stem cell infusion: IV administration of donor/autologous cells
Engraftment: 2-4 weeks (neutrophil recovery)

Complications:

Early: Infection, bleeding, mucositis, organ toxicity
Acute GVHD: Skin, liver, GI tract (first 100 days)
Chronic GVHD: Multiple organs (after 100 days)
Graft failure: Primary or secondary
Infections: Bacterial, viral (CMV), fungal
Veno-occlusive disease
Late effects: Infertility, secondary malignancies

Outcome:

Aplastic anemia: 70-90% cure rate in young patients with matched sibling donor
Thalassemia: 80-90% cure rate if transplanted before iron overload/hepatic damage
Sickle cell disease: >90% cure rate but reserved for severe cases due to risks

D. Surgical Interventions for Underlying Cause

1. Gastrointestinal Surgery:

Peptic ulcer bleeding: Endoscopic hemostasis, rarely surgery
Colorectal cancer: Surgical resection
Vascular malformations: Endoscopic ablation

2. Gynecological Surgery:

Hysterectomy or endometrial ablation: Severe menorrhagia refractory to medical therapy
Myomectomy: Uterine fibroids causing bleeding

3. Renal Transplantation:

End-stage renal disease: Corrects EPO deficiency, anemia improves

Other Therapeutic Interventions

A. Dietary Modifications

Iron-Rich Diet:

Heme iron sources (better absorbed):

Red meat (beef, lamb)
Poultry (chicken, turkey)
Fish and seafood (tuna, salmon, shellfish)
Organ meats (liver - highest source)

Non-heme iron sources (less bioavailable):

Dark green leafy vegetables (spinach, kale)
Legumes (beans, lentils, chickpeas)
Fortified cereals and bread
Dried fruits (raisins, apricots)
Nuts and seeds
Tofu

Enhancing Iron Absorption:

Consume with vitamin C sources (citrus fruits, tomatoes, bell peppers)
Cook in cast iron cookware
Avoid inhibitors with meals (tea, coffee, calcium, phytates)

B12-Rich Diet:

Animal products: Meat, poultry, fish, eggs, dairy
Fortified cereals and nutritional yeast (for vegetarians)
B12 supplementation essential for strict vegans

Folate-Rich Diet:

Dark green leafy vegetables (spinach, asparagus, broccoli)
Citrus fruits
Beans and legumes
Fortified grains and cereals
Liver

B. Oxygen Therapy

Indications:

Symptomatic severe anemia with hypoxia
Acute sickle cell crisis with acute chest syndrome
Bridging therapy until definitive treatment

Administration:

Nasal cannula (2-6 L/min)
Face mask (6-10 L/min)
Goal: Maintain SpO₂ >92%

C. Intravenous Fluids

Indications:

Acute blood loss with hypovolemia
Sickle cell vaso-occlusive crisis (hydration prevents sickling)

Types:

Normal saline (0.9% NaCl)
Lactated Ringer's

Caution: Avoid fluid overload (risk of TACO, heart failure)

D. Pain Management (particularly in sickle cell disease)

Acute Pain Crisis:

Opioid Analgesics:

Morphine, hydromorphone (IV/PO)
Patient-controlled analgesia (PCA)
Scheduled dosing, not PRN alone

NSAIDs:

Ketorolac (IV), ibuprofen (PO)
Adjunct to opioids

Non-pharmacological:

Heat application
Massage
Distraction, relaxation techniques

Chronic Pain:

Multimodal approach
Chronic opioids (avoid if possible)
Neuropathic pain medications (gabapentin)
Psychological support

E. Hydration and Exchange Transfusion (Sickle Cell)

Simple Transfusion:

Raises Hb, decreases HbS percentage
Acute chest syndrome, severe anemia

Exchange Transfusion (Erythrocytapheresis):

Removes HbS RBCs, replaces with normal RBCs
Indications:

Acute stroke
Severe acute chest syndrome
Multi-organ failure
Pre-operative preparation

Goal: Reduce HbS <30%

F. Phlebotomy (Therapeutic)

Indications:

Polycythemia vera (opposite of anemia, but related to RBC disorders)
Hemochromatosis (iron overload)

G. Gene Therapy (Emerging)

For Sickle Cell Disease and Thalassemia:

LentiGlobin therapy: Adds functional beta-globin gene
CRISPR/Cas9: Gene editing to reactivate fetal hemoglobin
Early results promising, not yet widely available

H. Supportive Care

Infection Prevention:

Hand hygiene
Avoid sick contacts
Vaccinations (influenza, pneumococcal, COVID-19)
Prophylactic antibiotics (post-splenectomy, sickle cell disease)

Nutritional Support:

Dietitian consultation
Nutritional supplementation if deficiencies
Total parenteral nutrition (TPN) if severe malabsorption

Psychological Support:

Counseling for chronic disease coping
Support groups
Depression and anxiety screening and treatment

Social Support:

Case management
Financial assistance programs
Home health services

8. Nursing Management

Assessment

Assess vital signs continuously, focusing on HR and RR.
Assess skin, mucous membranes, and conjunctiva for pallor.
Evaluate neurological status (confusion, dizziness, numbness/tingling in B12 deficiency).
Assess dietary history, menstrual history, and stool characteristics (melena).

Monitoring

Monitor daily lab results (CBC, Iron, Hematocrit).
Monitor for signs of fluid volume overload if receiving a blood transfusion.
Monitor medication side effects (e.g., constipation and black stools from oral iron).

Patient Care Interventions

Cluster nursing care to provide periods of uninterrupted rest.
Assist with Activities of Daily Living (ADLs) to prevent fatigue and falls.
Administer prescribed supplemental oxygen.
Provide a diet high in iron, protein, and vitamins.

9. Complications

Short-term Complications: Severe fatigue impairing daily life, syncope (fainting) leading to falls/injury, impaired cognitive function.
Long-term Complications: High-output congestive heart failure (CHF), arrhythmias, angina, cardiomegaly, maternal/fetal complications during pregnancy (preterm birth, low birth weight).

10. Prevention

Primary Prevention: Nutritional education promoting iron-rich and folate-rich foods (leafy greens, red meat, legumes); prophylactic iron for pregnant women.
Secondary Prevention: Routine Hb screening during pregnancy, well-child visits, and for menstruating women; early detection and intervention.
Tertiary Prevention: Ongoing management of chronic diseases (like chronic kidney disease) to prevent severe anemic episodes; preventing complications like heart failure through strict medication adherence.

11. Patient Education

Dietary Modifications: Teach the patient to consume iron-rich foods (spinach, liver, lentils). Advise pairing iron-rich foods with Vitamin C (citrus fruits) to enhance absorption. Avoid drinking tea or coffee with meals (tannins inhibit iron absorption).
Medication Adherence: Take oral iron on an empty stomach if tolerated. Warn the patient that stools may turn dark green or black. Encourage increased fluid and fiber intake to combat iron-induced constipation. Liquid iron should be taken with a straw to prevent teeth staining.
Follow-up Care: Emphasize the need for regular blood tests to monitor Hb levels and the importance of reporting symptoms like chest pain or extreme dizziness immediately.

12. Prognosis

The prognosis for anemia varies widely depending on the etiology. Nutritional anemias (iron, folate, B12 deficiency) have an excellent prognosis and are usually completely curable with proper supplementation and diet. Anemias caused by genetic disorders or chronic diseases require lifelong management, but with modern therapies, patients can maintain a good quality of life.

13. Conclusion

Anemia is a multifaceted condition that profoundly impacts a patient's oxygenation, energy levels, and overall well-being. Effective management requires a collaborative approach involving accurate diagnosis, medical intervention, and meticulous nursing care. Nurses play a pivotal role in identifying clinical signs, safely administering treatments such as blood transfusions, and educating patients on lifestyle and dietary modifications to prevent recurrence.

14. Nursing Care Plan (NCP)

Table 1: Comprehensive Nursing Care Plan for a Patient with Anemia

Assessment Data (Subjective & Objective)	Nursing Diagnosis (NANDA-I)	Goal/Expected Outcome (SMART)	Nursing Interventions	Scientific Rationale	Evaluation
Subj: Patient complains of "feeling exhausted all the time."<br>Obj: Hb: 8.5 g/dL, weak handgrip, requires frequent rest during bathing.	Fatigue related to decreased oxygen-carrying capacity of the blood as evidenced by verbal reports of exhaustion and inability to complete ADLs.	Goal: Patient will verbalize an increase in energy levels and actively participate in ADLs without excessive exhaustion within 3 days.	1. Assess patient's current level of fatigue and ability to perform ADLs.<br>2. Cluster nursing care and procedures.<br>3. Assist with ADLs as needed.<br>4. Encourage alternate periods of rest and activity.<br>5. Administer prescribed supplemental oxygen if indicated.<br>6. Administer blood transfusions or erythropoietin as prescribed.	1. Provides a baseline to evaluate the effectiveness of interventions.<br>2. Conserves patient energy and reduces cellular oxygen demand.<br>3. Prevents overexertion while ensuring basic hygiene and needs are met.<br>4. Pacing activities prevents exhaustion and promotes endurance.<br>5. Supplemental O2 increases the saturation of available hemoglobin, reducing tissue hypoxia.<br>6. Replaces depleted RBCs/Hb, directly addressing the physiological cause of fatigue.	Goal Met / Partially Met: Evaluate if the patient can perform basic ADLs with fewer rest periods and reports feeling less exhausted.
Subj: "I get out of breath just walking to the bathroom."<br>Obj: HR: 110 bpm, RR: 24 breaths/min with exertion, SpO2: 94% on room air.	Activity Intolerance related to imbalance between oxygen supply and demand secondary to decreased hemoglobin levels.	Goal: Patient will demonstrate improved activity tolerance as evidenced by maintaining HR <100 bpm and RR <20 breaths/min during mild exertion within 48 hours.	1. Monitor vital signs (HR, RR, BP) before, during, and after activity.<br>2. Instruct the patient in energy conservation techniques (e.g., sitting while showering).<br>3. Teach deep breathing exercises.<br>4. Gradually increase physical activity as tolerated.<br>5. Keep essential items (water, call bell) within easy reach.	1. Identifies cardiopulmonary stress and dictates the safe limits of patient activity.<br>2. Reduces energy expenditure and oxygen demand during necessary daily tasks.<br>3. Enhances lung expansion and maximizes oxygen uptake.<br>4. Rebuilds muscle endurance and prevents complications of immobility without causing hypoxia.<br>5. Reduces unnecessary physical exertion.	Goal Met / Partially Met: Evaluate HR and RR during ambulation to see if they remain within the target parameters.
Subj: "I haven't had much of an appetite lately."<br>Obj: BMI: 18.0, pale mucous membranes, diet recall shows lack of iron-rich foods, Serum Iron: Low.	Imbalanced Nutrition: Less than Body Requirements related to inadequate intake of essential nutrients (iron, B12, folate) for erythropoiesis.	Goal: Patient will consume at least 80% of provided meals and identify 5 iron-rich foods to include in their diet prior to discharge.	1. Assess nutritional history, dietary preferences, and barriers to eating.<br>2. Provide a diet high in iron (lean meats, spinach, legumes), vitamin B12, and folic acid.<br>3. Encourage intake of Vitamin C-rich foods (citrus fruits) with iron sources.<br>4. Advise avoiding tea or coffee during meals.<br>5. Administer oral iron supplements as prescribed, offering them between meals.	1. Identifies deficits and cultural preferences to individualize the diet plan.<br>2. Provides the necessary raw materials required by the bone marrow for healthy RBC production.<br>3. Ascorbic acid (Vit C) significantly enhances the gastrointestinal absorption of non-heme iron.<br>4. Tannins in tea and coffee inhibit the absorption of dietary iron.<br>5. Iron is absorbed best in an acidic environment (empty stomach), though it may need to be given with food if GI upset occurs.	Goal Met / Partially Met: Check meal trays post-meal for 80% consumption; ask the patient to list 5 iron-rich foods.
Subj: "I feel dizzy when I stand up too fast."<br>Obj: Orthostatic hypotension noted (BP drops from 110/70 lying to 90/60 standing), unsteady gait.	Risk for Falls related to dizziness, weakness, and orthostatic hypotension secondary to tissue hypoxia.	Goal: Patient will remain free from falls and injury throughout the hospital stay.	1. Assess neurological status, balance, and orthostatic vital signs.<br>2. Instruct the patient to change positions slowly, especially from lying to standing (dangle legs first).<br>3. Keep the bed in the lowest position with wheels locked and side rails up as per policy.<br>4. Ensure non-slip footwear is worn when ambulating.<br>5. Assist with ambulation and provide a gait belt if unsteady.	1. Identifies the patient's specific risk level for syncope and falls.<br>2. Allows time for the baroreceptors to adjust to position changes, preventing sudden cerebral hypoxia and fainting.<br>3. Provides a safe environment and minimizes the distance of a potential fall.<br>4. Prevents slipping on smooth hospital floors.<br>5. Provides physical support and immediate intervention if the patient loses balance.	Goal Met: Evaluate if the patient remained fall-free and followed position-change instructions during the shift.
Subj: "I don't know why my stool is black, I think I'm bleeding."<br>Obj: Patient recently started on oral Ferrous Sulfate. Anxious facial expression.	Deficient Knowledge related to new medication regimen and dietary management of anemia as evidenced by misconceptions about treatment side effects.	Goal: Patient will correctly explain the purpose, side effects, and administration guidelines of iron therapy within 24 hours.	1. Assess the patient's baseline knowledge and readiness to learn.<br>2. Explain the purpose of iron supplements in treating anemia.<br>3. Educate that dark green or black stools are a normal, expected side effect of oral iron.<br>4. Instruct the patient to increase fluid and dietary fiber intake.<br>5. Provide written educational materials regarding iron-rich diets and medication guidelines.	1. Facilitates tailored education based on the patient's current understanding.<br>2. Promotes adherence by helping the patient understand the rationale for treatment.<br>3. Relieves anxiety associated with unexpected physical changes and prevents false alarms of GI bleeding.<br>4. Oral iron is highly constipating; fiber and fluids promote normal bowel motility.<br>5. Written materials reinforce verbal teaching and serve as a reference at home.	Goal Met: Ask the patient to teach-back the expected side effects of iron and how to prevent constipation.

15. References

Berman, A., Snyder, S., & Frandsen, G. (2020). Kozier & Erb's fundamentals of nursing: Concepts, process, and practice (11th ed.). Pearson.
Harding, M. M., Kwong, J., Roberts, D., Hagler, D., & Reinisch, C. (2019). Lewis's medical-surgical nursing: Assessment and management of clinical problems (11th ed.). Elsevier.
Herdman, T. H., Kamitsuru, S., & Lopes, C. T. (Eds.). (2021). NANDA International nursing diagnoses: Definitions and classification 2021-2023 (12th ed.). Thieme.
Hinkle, J. L., & Cheever, K. H. (2018). Brunner & Suddarth's textbook of medical-surgical nursing (14th ed.). Wolters Kluwer.
World Health Organization (WHO). (2021). Anaemia. https://www.who.int/health-topics/anaemia

Disclaimer:

The information provided in this document is intended for educational and academic purposes only and should not be construed as professional medical advice, diagnosis, or treatment. It is designed solely to assist nursing students in their studies. In clinical practice, always consult a qualified healthcare provider for patient care decisions and strictly adhere to your facility's specific clinical guidelines, protocols, and the most current evidence-based practices, as medical knowledge and nursing standards are subject to continuous change.

Nursing Wisdom Hub

Search This Blog

Comprehensive Nursing Assignment: Anemia

Comments

Post a Comment